New approvals for fam-trastuzumab deruxtecan-nxki establish a potential new standard of care in the neoadjuvant and adjuvant settings for patients with HER2-positive early breast cancer.

FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...

The U.S. Food and Drug Administration has approved Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and ...

Market impact includes expansion from metastatic into early-stage HER2-positive disease, intensifying competition with ...

New trastuzumab deruxtecan indications cover neoadjuvant and adjuvant treatment ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Treatment with T-DXd resulted in a statistically significant and clinically meaningful improvement in IDFS vs T-DM1. Topline results were announced from a phase 3 trial comparing fam-trastuzumab ...

Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, Kadcyla), according to long-term follow-up of a large clinical trial. Estimated ...

Across five studies that evaluated trastuzumab emtansine, the pooled incidence of decrease in LVEF was 1.09% (95% CI, 0.63%-1.88%), and after trim‑and‑fill ...

Pemetrexed and Cisplatin for the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix: A Limited Access Phase II Trial of the Gynecologic Oncology Group The antibody–drug conjugate ...

The FDA has approved two new indications for trastuzumab deruxtecan (Enhertu) in patients with early-stage HER2-positive ...